We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FOR:NYSEForestar Group Inc Analysis

Data as of 2026-04-04 - not real-time

$24.64

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Forestar Group (FOR) trades at $24.64, well below its DCF fair value of $40.54 and a trailing P/E of 7.5 versus an industry average of 32, indicating a substantial valuation gap. Operating margins sit at 4.7% with a modest profit margin of 9.9%, and the balance sheet is strong, featuring $318.8M in cash against $111.7M of debt (debt‑to‑equity ~16.6%). Technical indicators show the price near the support level of $23.96, with a neutral trend, RSI at 40, and a bullish MACD histogram (+0.03) amid increasing volume, suggesting limited downside pressure. The upcoming Q2 earnings release on April 21 adds a short‑term catalyst that could confirm the upside potential.
Risk metrics reveal a 30‑day volatility of 28.5% and a beta of 0.8, reflecting moderate market sensitivity, while the company’s U.S.-focused land development model limits geographic and currency exposure. Given the undervalued pricing, solid cash generation, and upcoming earnings catalyst, the stock presents a compelling entry point for value‑oriented investors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near technical support with bullish MACD signal
  • Significant valuation discount to DCF and industry multiples
  • Upcoming Q2 earnings release providing catalyst

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained cash flow and low leverage supporting earnings stability
  • Undervalued relative to peers offering upside as market re‑rates
  • Moderate volatility and beta indicating manageable market risk

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong balance sheet with ample cash and low debt
  • Consistent profitability despite flat revenue growth
  • Long‑term real‑estate development demand in the U.S. market

Key Metrics & Analysis

Financial Health

Revenue Growth-3.00%
Profit Margin9.90%
P/E Ratio7.5
ROE9.81%
ROA4.25%
Debt/Equity16.56
P/B Ratio0.7
Op. Cash Flow$95.3M
Free Cash Flow$137.5M
Industry P/E32.0

Technical Analysis

TrendNeutral
RSI40.2
Support$23.96
Resistance$26.29
MA 20$25.03
MA 50$26.82
MA 200$25.67
MACDBullish
VolumeIncreasing
Fear & Greed Index78.8

Valuation

Fair Value$40.54
Target Price$33.00
Upside/Downside33.93%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.80
Volatility28.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.